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“TROICA” HEALTH CARE ECONOMICS IN GREECE
Kyriopoulos E1, Mylona K2, Tsiantou V2, Kyriopoulos J2
1University of Athens, Athens, Greece, 2National School of Public Health, Athens, Greece
OBJECTIVES: On May 2010 Greece reached an agreement with a joint team of the
International Monetary Fund, the European Commission and the European Central
Bank, as the country faced severe fiscal problems. According to the Agreement,
public pharmaceutical expenditure should be reduced from 1.9% to 1% of GDP,
while the reduction on health services and social security expenditure should be
accounted for 1.5 billion euros and 1.2 respectively. The aim of the study was to
evaluate the progress of the measures taken and to estimate their impact on health
expenditure and provision of services.METHODS: For the purpose of the study, we
used data from the Stand-By Arrangement and its reviews, Hellenic Statistical
Authority and Greek System of National Accounts, as well as published data in the
literature. RESULTS: The cuts of wages in public and private sector (15%) and the
increase of unemployment (from 9% to 15%) resulted in increased demand for
public hospital care by 24% as a consequence of reduced demand (30%) in hospital
units of private sector, while a decrease in demand for primary health care in both
public and private sector by 10% and 35% respectively was observed. In addition,
the cost of time in public hospitals is steadily increased, due to surgical interven-
tions and the use of high technology services, as well as because of reductions on
hospital budgets for medical equipment procurements. CONCLUSIONS: Although
the impact of the implemented reforms and policies in private health expenditures
is already visible the significant reduction of health services inputs causes a de-
crease in quantity and quality of services. The need for balanced development
relating both to supply and demand side requires structural reforms in healthcare
sector as well as transition from a costly technological model to a health system
based on primary care and public health.
PHP141
IN SEARCH OF REFORM FOR THE GREEK HEALTH CARE SYSTEM: DEPICTING
THE KEY OPINION LEADERS’ VIEWS
Tsiantou V, Athanasakis K, Pavi E, Kyriopoulos J
National School of Public Health, Athens, Greece
OBJECTIVES: Financial crisis in Greece raised the need for more efficient use of
resources in the health care sector. A number of policies have been proposed for
this purpose. The aim of this study was to investigate the views of healthcare Key
Opinion Leaders (KOLs) on the proposed interventions. METHODS: Seventy-two
KOLs were invited to participate in an expert panel survey. For the purpose of the
study a closed questionnaire was developed comprising of six sections based on
the proposed policies i.e. audit, economic evaluation, financial management, pric-
ing, health care funding and procurement system. During the meeting KOLs were
asked to select the answers that best represented their views on the appropriate-
ness/feasibility of each policy under study and express their opinion in an open
discussion that followed. RESULTS: Forty experts (55.5%) accepted the invitation.
The majority of participants argued that audit is necessary in the health sector but
half of them believed that at present it is not feasible. They thought that a certified
public institution should be responsible for the audit process. The indicators and
targets should be set nationally but can be differentiated locally. Very important
was the finding that the audit report should be a criterion for each institution’s
(hospital) funding and if results are negative then a penalty should be applied.
Implementation of economic evaluation in decision-making was considered ex-
tremely important. A reform in the hospital’s financing was reported as necessary
and the most suitable reimbursement technique is a combination of global budget
and DRG system. Physicians should be reimbursed based on qualitative criteria.
Finally, procurement system should and can be reformed immediately according
to the expert panel. CONCLUSIONS: All proposed interventions were evaluated
positively but experts considered that there is a greater need for an audit mecha-
nism and reform of the procurement system to be implemented first.
Health Care Use & Policy Studies – Risk Sharing/Performance-Based Agreements
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LANDMARK CER STUDY METHODS REVIEW
Cummins G, Britton K, Doyle J
Quintiles, Hawthorne, NY, USA
OBJECTIVES: Comparative effectiveness research (CER), constitutes a ‘real-world’
comparison of the risk-benefit profile of a new product with the existing standard
of care. In the US, the federal government is supporting the expansion of CER
through funding made available in the American Recovery and Reinvestment Act
of 2009 (ARRA) and by establishing the Patient-Centered Outcomes Research Insti-
tute through the Patient Protection and Affordable Care Act of 2010. Similarly in
Europe there is push for relative effectiveness studies. Industry and governments
have deployed a variety of experimental research design methods to appraise real-
world performance of products vis-à-vis competitors. An evaluation of five recent
studies was analyzed to assess CER implications. METHODS: We performed a
structured review and assessment of five different therapeutic classes (antihyper-
lipidemics, antipsychotics, antiplatelets, anti-VEGF, and insulin analogues) inves-
tigated in CER related studies (AIM-HIGH, CATIE, GeCCO, CATT, and AHRQ CER
Premixed Insulin Analogues). CER metrics included study population including
comparative agent(s), relevance of conclusions and interpretations outside the
study population. RESULTS: Study designs varied including head to head, study
agent versus placebo, and systematic literature reviews as well as various types of
metrics (safety, efficacy, and effectiveness). One study was stopped early due to
lack of benefit, three studies determine equivalence of effectiveness (cost, clinical).
Another study is still underway (GeCCO) with results expected towards the end of
2011. CONCLUSIONS: The number of CER focused studies is increasing with wide
variability in study designs, comparators, populations, and endpoints. With the
surge of new agencies dedicated to this evolving field of research (e.g., PCORI in the
US), it will be important to evaluate the various types of CER studies and resulting
information from a multi-stakeholder perspective.
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MULTI-STAKEHOLDER SURVEY OF COMPARATIVE EFFECTIVENESS RESEARCH
PERCEPTIONS
Cummins G, Duong A, Doyle J
Quintiles, Hawthorne, NY, USA
OBJECTIVES: Comparative effectiveness research (CER) is designed to inform
health care decision making through evidence generation on relative benefit for
treatment options to multiple stakeholders. Payors have experience utilizing self-
generated CER information to inform policy decisions including: formulary tier
placement, prior authorization requirements, other utilization control techniques,
and cost control mechanisms. However, wide acceptance and regular use of CER
has yet to be fully realized. The Quintiles New Health Report 2011 survey assessed
how and to the extent national payors were receptive to the implementation of
CER. METHODS: The New Health Report 2011, designed by Quintiles, surveyed
multiple stakeholders to better understand each stakeholder’s perceptions toward
health care, focusing on perceived value. More than 200 biopharmaceutical exec-
utives, 153 managed care executives, 500 physicians, and 30 MCOs were sampled in
the survey. The focus was payor perspective in relation to value and CER. RESULTS:
Though the vast majority of payors valued CER and vocalized their desire for more
CER data, fewer than half of payors actively promoted CER on their websites or in
published literature. Some payors do advocate and sometimes require CER data
from manufacturers, 85% of surveyed payors utilized self-generated CER data
rather than data provided by manufacturers. Biopharmaceutical executives were
overwhelming in agreement to invest more in long-term outcomes data, but only
44% had even access readily available outcomes data to demonstrate value, while
38% admitted that they did not have any access at all to CER information.
CONCLUSIONS: A large percentage of payors recognize the short/long term value
and utility of CER data, but are not accessing the available data and/or are not sure
how to access the data. To encourage greater utilization of CER, stakeholders must
be more assertive in capturing and evaluating CER information, while partnering
together to create more transparent and standardized CER guidelines.
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THE BURDEN OF EVIDENCE IN THE PHARMACEUTICAL APPRAISAL PROCESS
Brooks-Rooney C, Costello S, Timm B, Leonard SA, Hamer N
Costello Medical Consulting, Cambridge, UK
OBJECTIVES: The emergence of evidence-based medicine (EBM) in the past decade
has raised the level of the scientific data required during the drug appraisal pro-
cess. It is no longer sufficient to prove that a new treatment is better than placebo
in one clinical trial; healthcare decision makers additionally require information
on how it performs in multiple trials, including against other treatments in the
disease area. Systematic reviews, meta-analyses, comparative effectiveness stud-
ies and head-to-head trials are becoming essential in the appraisal process as
decision makers demand higher levels of evidence from manufacturers. This anal-
ysis reviewed PubMed articles for trends in the numbers of such studies from
2001-2010. METHODS: The titles of PubMed articles were searched for “systematic
review”, “meta-analysis”, “comparative effectiveness” and “head-to-head” along
with the year of publication. RESULTS: The mean annual change in the number of
articles indexed by PubMed over the period was 6.0%, which represents the back-
ground increase in the body of scientific evidence. In contrast, the mean annual
change for systematic reviews was 27.4% (from 388 in 2001, to 3406 in 2010), 23.2%
for meta-analyses (462 to 2,996), 80.5% for comparative effectiveness studies (5 to
247) and 23.1% for head-to-head trials (11 to 53). These increases are all substan-
tially higher than the background increase in PubMed articles. The increase in
comparative effectiveness studies in particular illustrates the strength of interest
in this area of research. CONCLUSIONS: EBM is now accepted globally as the pre-
ferred method of appraising new treatments; as the pharmaceutical industry
adapts to this landscape, the number of studies examining the evidence base has
increased considerably in the past decade. The next movement in the industry has
already arrived, that of direct comparative effectiveness, and whilst the number of
head to head studies has already increased we can expect to see further increases
over the next decade.
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CURRENT STATUS AND TRENDS IN PERFORMANCE-BASED SCHEMES BETWEEN
HEALTH CARE PAYERS AND MANUFACTURERS
Carlson JJ1, Gries K2, Sullivan SD1, Garrison L3
1University of Washington, Seattle, WA, USA, 2University of Washington, Newport Beach, CA,
USA, 3University of Washington Department of Pharmacy, Seattle, WA, USA
OBJECTIVES: To identify and characterize publicly available cases and related
trends for performance-based schemes. METHODS: We performed a systematic
review of performance-based schemes over the past 15 years (1996 – 2011) using
publicly available databases and reports from colleagues and health care experts.
These were categorized according to a previously published taxonomy of scheme
types and assessed in terms of the underlying product and market attributes for
each scheme. Macro-level trends were identified related to the timing of scheme
adoption, countries involved, types of schemes, and product and market factors.
RESULTS:Our search yielded in excess of 110 schemes. From this set, we identified:
A359V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
58 schemes that included a coverage with evidence development component, 25
that included a conditional treatment continuation component, 35 that included a
performance-linked reimbursement component, and 37 that included a patient
level financial utilization component. Each type of scheme addresses fundamental
uncertainties that exist when products enter the market. There has been a contin-
ued upward trend in terms of total schemes adopted per year and the number of
countries with performance-based schemes in place. Despite the continued enthu-
siasm, challenges persist including those related to: 1) the cost and burden of
implementation; 2) the need for consistent processes for scheme development,
data collection, reporting, and evaluation; and 3) negotiating follow-on agreements
after scheme initiation. Furthermore, the challenges faced differ by country, health
system, and product. CONCLUSIONS: There is continued enthusiasm in many
countries for using performance-based schemes for new medical products. Given
the interest to date and the potential to meet the goals of interested stakeholders,
these schemes may become a common element in health care coverage and reim-
bursement. However, significant challenges persist, and future studies are needed
regarding the attitudes and perceptions of various stakeholders as well as evalu-
ating the results and experiences with the schemes implemented thus far.
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OPINIONS ON MARKET ACCESS NEEDS DIFFER BETWEEN CULTURES AND
STAKEHOLDER SECTORS – RESULTS OF A SURVEY OF ISPOR DELEGATES
Kyral A, Johnson KI
Complete Medical Group, Macclesfield, Cheshire, UK
OBJECTIVES: To determine whether stakeholders’ opinions on market access is-
sues, in particular the need for QALYs, and risk-sharing, differ by sector and geo-
graphical location.METHODS: A self-completion questionnaire was presented to a
cross section of delegates at the 13th European ISPOR Conference 2010. The ques-
tionnaire comprised 7 items, with both ordinal-polytomous Likert scales and open
ended responses. Analyses were performed to discriminate between the stake-
holder groups including Pearson Chi-squared test of independence, cross-tabula-
tions, and other descriptive statistics for nominal categorical data. The level of
agreement between responder groups was obtained from Cohen’s Kappa coeffi-
cients and radar plots. RESULTS: Respondents included representatives of over 60
companies and organisations from over 30 countries. Highly significantly different
responses were observed between members from European and non-European
countries, with the greatest overall level of agreement being between the industry
and academic sectors (87.5%, K0.75). Fewer respondents from European countries
favoured the use of the QALY than those from non-European countries (31.8% vs.
69.2%), whilst significantly more academics favoured the QALY than either indus-
try or agency respondents (62.1% vs 36.6% vs. 21.4% respectively). More academics
felt that manufacturers should offer patient access schemes (PAS) routinely (41.4%
vs. 19.4% vs. 14.3%). Of non-European respondents, 50.0% felt risk sharing should
form part of all health technology assessments compared with only 25% of respon-
dents from European countries. The majority of non-European respondents (53.8%)
expressed the need for manufacturers to provide PAS routinely; only 16.3% of Eu-
ropean respondents agreed. Only 13.3% of respondents from European countries
thought indirect comparisons are a substitute for head-to-head trials, compared
with 38.5% of respondents from non-European countries. No other significant dif-
ferences in opinions on the need for cost-utility analysis or cost-per-QALY thresh-
olds were found. CONCLUSIONS: Opinions on market access related issues differ
significantly between European and non-European ISPOR members, and between
stakeholder groups.
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GLOBAL PHARMACEUTICAL RISK-SHARING AGREEMENT TRENDS IN 2010 AND
2011
Ando G1, Reinaud F2, Bharath A3
1IHS, London, UK, 2IHS, Paris, France, 3IHS, London, London, UK
OBJECTIVES: With payors increasingly looking at ways of cutting pharmaceutical
reimbursement costs, pharmaceutical companies need to consider creative solu-
tions to market access for new compounds. The objective of this research was to
examine the most recent global trends for 2010 and 2011 in pharmaceutical risk-
sharing agreements, which are now a critical part of market access strategies in
many countries. METHODS: Secondary research was conducted examining reim-
bursement decisions around the world, with a special focus on Australia, Belgium,
Canada, China, France, Germany, Hungary, Italy, The Netherlands, New Zealand,
Poland, Spain, UK and United States. This was supplemented by primary research
with payors, government agencies and HTA organisations through interviews in
native languages to understand the role which risk-sharing agreements have – or
have not – played in their respective markets. RESULTS: Forty-five new risk-shar-
ing agreements were found under the period of review (January 2010-May 2011),
nearly double the total for 2009. Of the new agreements, the majority were finance-
based agreements, though there were six new examples of performance-based
agreements. 40% of the new agreements were concluded with the UK’s NICE, whilst
Australia and Italy remain other important markets in this area. However, a signif-
icant number of newer countries are beginning to see these agreements, including
Belgium, Hungary, Poland and New Zealand, and interest is widening in emerging
markets. Around half of the agreements were in the oncology area, but there are
signs that risk-sharing is becoming increasingly prominent in other therapeutic
areas, including blood disease, mental health, pain treatment, immunology, oph-
thalmology and cardiovascular care. CONCLUSIONS: Risk-sharing agreements are
a reality for pharmaceutical companies in many key markets, and need at least to
be considered as an alternative market access strategy in certain therapeutic areas.
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PERCEPTION OF PHARMACEUTICAL COMPANIES ON THE DRUG PRICE-VOLUME
NEGOTIATION IN SOUTH KOREA
Kim ES1, Lee BJ1, Lee EK2
1GlaxoSmithKline Korea, Seoul, South Korea, 2Sookmyung Women’s University, Seoul, South
Korea
OBJECTIVES: In Korea, although drug price has continuously decreased due to
many price reduction mechanisms, the volume has been increasing. Because this
risen volume is considered a main contributor of increasing pharmaceutical ex-
penditure, the government adopted price-volume negotiation in 2006. This study
attempted to analyze the status of price-volume (PV) negotiation and identify prob-
lems and the solutions to improve the price-volume negotiation. METHODS: The
comprehensive questionnaire was designed based on Korea price negotiation
guideline and validated by three pilot interviewers. It consisted of the status,
awareness, satisfaction, problems/solutions. Pharmaceutical company’s people
involved in market access were interviewed face-to-face. The response rate was
80% (n34). Multinational and local company accounted for 59% and 41%,
respectively. RESULTS: Most important factors for PV negotiation were budget
impact and price from the Korean PV formula. 69% of 16 PV cases were derived from
the price calculated by PV formula and only 42% reached the consensus on budget
impact because of different data sources. Most respondents agreed with the objec-
tive of the risk-sharing system but the overall satisfaction was significantly low, 1.9
out of 5-point scale. Main reasons are unpredictability of selecting PV product,
discreditable NHIC data and non-transparency of the negotiation process. Also,
76.5% of respondents was against PV negotiation because of the government’s
unnecessary intervention and concerns on weakening the pharmaceutical indus-
try. Especially, respondents worried about profit deterioration due to duplicated
price reduction. In response, they suggested the advanced PV model with a more
specific PV inclusion criteria and the choice between price reduction and pay-back.
Additionally, generic promotion and pay-back system activation to contain the
drug expenditure are preferred over price-volume negotiation. CONCLUSIONS:
The price-volume negotiation in Korea must be improved to motivate the pharma-
ceutical industry through adopting their opinions on advanced PV model which
includes pay-back.
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PHARMACEUTICAL PRICING UNDER UNCERTAINTY: RISK-SHARING
CONTRACTS
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OBJECTIVES: Pharmaceutical pricing decisions are adopted in a context of uncer-
tainty with regard to the efficacy and safety of the drug as well as to their budgetary
implications. Traditionally, pharmaceutical firms have received a fixed price per
unit sold regardless of health outcomes and sales volume. This pricing policy tends
to increase health budgets and may restrict the access to pharmaceutical innova-
tions for patients. Recently, health authorities have begun to use risk-sharing con-
tracts based on health outcomes to cope with the aforementioned problem. In this
paper, we carry out a theoretical modelling of the risk-sharing contracts, empha-
sizing the variables and parameters that are relevant in the relationship between
health authorities and pharmaceutical firms. METHODS: We have elaborated a
theoretical model that describes the interaction between a pharmaceutical firm
and a public health authority using a two-stage game. In the first stage, the health
authority chooses the pricing policy, either paying to the firm for treated patient or
for cured patient, and in the second stage, the firm, given the pricing policy and the
prescribing behaviour of the physicians, selects the price that maximizes its ex-
pected profits. We solve the game by backward induction, using the subgame per-
fect equilibrium as the solution concept. RESULTS: Risk-sharing contracts are not
always optimal in terms of social welfare. Their optimality depends on the param-
eters of the problem, being conditioned by the prescribing behaviour of the physi-
cians, the efficacy of the drug and the monitoring costs. We characterize the para-
metric regions for which each pricing policy is socially optimal. CONCLUSIONS:
Before using risk-sharing contracts, their convenience must be addressed for each
particular case. As a necessary condition, the existence of objective quantitative
health indicators is required. Otherwise, it is difficult to implement the pricing
policy only based on cured patients.
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EVIDENCE ON THE IMPACT OF MANAGED ENTRIES ON PAYERS, PATIENTS,
MANUFACTURERS, AND HEALTH CARE WORKERS
Ferrario A, Nicod E, Kanavos P
London School of Economics and Political Science, London, England, UK
OBJECTIVES: Managed entries (MEs) are innovative pricing and reimbursement
agreements aiming to share the risk related to the introduction of new, high-cost
drugs between the payer and the manufacturer. This study aims to review evidence
on the impact of MEs on payer, patients, manufacturer, and health care workers
and to analyse emerging trends in managed entries at international level.
METHODS:A systematic literature review (grey and peer-reviewed) was performed
complemented by search of health technology assessment agency’s websites and
selective interviews with decision makers in key European countries. RESULTS:
Evidence exists of improved cost-effectiveness and lower drug price following the
implementation of coverage with evidence development in Sweden. Data from
France shows that price-volume agreements led to rebates totalling around 3% of
the total drugs bill. Evidence from Italy shows that authorization with a risk-shar-
ing agreement was associated with more rapid patient access in comparison to
authorization without such an agreement. It is unclear whether managed entries
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